12:00 AM
 | 
Apr 16, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/13 cls
Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) Bloom Burton Philippa Flint Upgrade Hold (from sell) -6% $0.59
Flint upgraded after the price fell below her $0.60 target following Cardiome's announcement last month that partner Merck & Co. Inc. (NYSE:MRK) discontinued development of the oral formulation of vernakalant for atrial fibrillation (AF) (see BioCentury, March 26). Flint sees no events that would drive value in the near-term and cautions the shares will be constrained until Cardiome unveils an attractive business strategy. She expects management to announce plans next half.
Halozyme Therapeutics Inc. (NASDAQ:HALO) Jefferies Eun Yang Downgrade Hold (from buy) -10% $11.27
Yang downgraded based on a "likely slow uptake" of Halozyme's three subcutaneous formulations of partnered products. Yang said a survey of

Read the full 894 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >